Global Health Innovators recognised with Abu Dhabi Global Health Week Innovation Awards for transformative impact
ABU DHABI, UAE, April 16, 2025 /PRNewswire/ -- Abu Dhabi Global Health Week (ADGHW) today honoured exceptional individuals and institutions from around the world whose innovative contributions are advancing the future of health. Winners of the ADGHW Innovation Awards 2025 were recognised for pioneering solutions in digital health, biotechnology, and diagnostics, receiving global recognition and a share of the $200,000 prize fund.
With a total of 91 submissions received from global and local individuals and institutions, the ADGHW Innovation Awards, sponsored by e& and PureHealth, welcomed entries that address critical health challenges across digital health, pharmaceutical and biotechnology innovations, and medical devices and diagnostics. Winners were selected following a rigorous review process led by a distinguished panel of global health experts, policymakers, and technology leaders.
ADGHW Innovation Awards recipients include:
The award ceremony commenced with opening remarks by H.E. Dr. Mansoor Ibrahim Al Mansoori, Chairman of the Department of Health – Abu Dhabi, who underscored the award's pivotal role in recognising excellence, fostering innovation, and accelerating progress across the healthcare sector. The event brought together senior government officials, healthcare leaders, and industry partners, including H.E. Dr. Jaleela bint Al-Sayed Jawad Hasan, Minister of Health of the Kingdom of Bahrain; H.E. Dr. Mikheil Sarjveladze, Minister of Internally Displaced Persons from the Occupied Territories, Labour, Health and Social Affairs of Georgia; Shaista Asif, Group Chief Executive Officer of PureHealth; Dr. Patrick Horber, President, International of Novartis; and Jacob Thaysen, Chief Executive Officer of Illumina.
Commenting on the winners' announcement, H.E. Dr. Noura Khamis Al Ghaithi, Undersecretary of DoH, said: "We are delighted to honour these trailblazers from around the world. Their achievements show how powerful innovation can be in changing the global health landscape and highlight what's possible when we work together. By celebrating these breakthroughs, we're not only recognising what's been accomplished today, we are also paving the way for a healthier tomorrow for all, where everyone enjoys well-being and a long, healthy life."
Submissions were evaluated based on originality, impact, scalability, and sustainability. The rigorous assessment process was overseen by a panel of esteemed experts in healthcare, digital health, and public policy including Dr. Asma Ibrahim Al Mannaei, Executive Director of the Health Life Sciences Sector at DoH; Professor Shafi Ahmed, multi-award-winning surgeon, teacher, futurist, innovator and entrepreneur; John Nosta, president of NostaLab, Lina Shadid, Middle East Health Industries Lead and Zubin Daruwalla, Asia Pacific Health Industries Lead at PwC.
"The ADGHW Innovation Awards exemplify the transformative power of collaboration and innovation in addressing global health challenges with creativity, rigour, and purpose. The diversity and ingenuity of the application submissions highlight Abu Dhabi's role in boosting an ecosystem that drives advancements in healthcare. At PwC, we are proud to support this initiative and contribute to shaping a future where innovation is both encouraged and celebrated," stated Lina Shadid, Middle East Health Industries Lead at PwC.
The diverse group of applicants underscores ADGHW's pivotal role in enhancing international collaboration and demonstrates Abu Dhabi's commitment to nurturing a thriving ecosystem that drives advancement of the global health sector.
In a first for the awards, an AI assistant was also integrated into the review process, supporting the jury by surfacing patterns, providing comparative insights, and complementing human expertise during deliberations. This hybrid model reflects ADGHW's commitment to harnessing the potential of emerging technologies to drive fairness, transparency, and efficiency in the evaluation of innovative ideas.
ADGHW is a major government initiative from DoH and serves as a platform for innovation and collaboration under the theme 'Towards Longevity: Redefining Health and Well-being.' It places a strong emphasis on community-driven health and well-being, with a proactive approach centred around preventive, personalised, and holistic care.
Four core themes will guide discussions and initiatives: Longevity and Precision Health; Health System Resilience & Sustainability; Digital Health & AI; and Investment in Life Sciences. By convening diverse stakeholders from around the world, ADGHW is a community without borders that seeks to advance the future of health and well-being.
About Abu Dhabi Global Health Week:
Abu Dhabi Global Health Week (ADGHW) is a major government-led initiative by the Department of Health – Abu Dhabi (DoH). It drives transformative innovation and collaboration under the theme 'Towards Longevity: Redefining Health and Well-being'. ADGHW serves as a year-round 'always-on' platform with a proactive approach centred around preventive, personalised, and holistic care. Held with and for the world, ADGHW is a platform for open, inclusive exchange, and joint action.
ADGHW welcomes entrepreneurs, policymakers, researchers, innovators, and investors to transform ideas into action, and collaborate around topics like advancing precision care and building a resilient technology-driven ecosystem. ADGHW 2025 proudly collaborates with key strategic partners, including Foundation Partner, M42 and Global Health and Longevity Champion, PureHealth. Additional exhibitors and sponsors include Burjeel, GSK, Johnson & Johnson, Lilly, Microsoft, Novo Nordisk, Viatris, Novartis, Roche, Cleveland Clinic Abu Dhabi, Deloitte, Gilead, Juvenescence, NYU Abu Dhabi and Pfizer, united in their commitment to advancing the future of healthcare and life sciences.
For more information on ADGHW, visit https://www.adghw.com/
For media registration visit, https://www.adghw.com/forms/media-registration/
For media inquiries or interview opportunities, please contact:
Maroun Farah, Senior Media Relations Manager, Weber Shandwick E: mfarah@webershandwick.com T: +971 55 166 2557
About the Department of Health – Abu Dhabi (DoH):
The Department of Health – Abu Dhabi is the regulative body of the healthcare sector in the Emirate of Abu Dhabi. Committed to ensuring excellence in healthcare, DoH monitors the health status of the population while shaping the regulatory framework for the health system. This includes inspecting against regulations, enforcing standards and encouraging the adoption of world-class best practices and performance targets by all healthcare providers in the Emirate. Abu Dhabi remains dedicated to shaping the future of healthcare by establishing an intelligent and sustainable ecosystem that prioritises health, longevity and quality of life for all community members. Leveraging state-of-the-art infrastructure and cutting-edge capabilities, DoH continues to develop and implement initiatives and programmes in line with its strategic focus areas, Healthy Population, Best-in-Class Care and Resilience and Innovation. These efforts reflect DoH's unwavering commitment to predicting, preventing and personalising healthcare for every individual.
Photo - https://mma.prnasia.com/media2/2666336/ADGHW_1.jpg?p=medium600
Photo - https://mma.prnasia.com/media2/2666340/ADGHW_2.jpg?p=medium600
Photo - https://mma.prnasia.com/media2/2666341/ADGHW_3.jpg?p=medium600
Photo - https://mma.prnasia.com/media2/2666337/ADGHW_4.jpg?p=medium600
Photo - https://mma.prnasia.com/media2/2666339/ADGHW_5.jpg?p=medium600
Logo - https://mma.prnasia.com/media2/2666335/Abu_Dhabi_Global_Health_Week_Logo.jpg?p=medium600
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
21 hours ago
- Korea Herald
HTL Biotechnology inaugurates a new production line dedicated to sterile hyaluronic acid
JAVENÉ, France, June 6, 2025 /PRNewswire/ -- On the occasion of National Bioproduction and Biomedicines Day (JNBB), which enjoys the high patronage of the President of the French Republic, HTL Biotechnology confirms its position as a globalleader in the development and production of pharmaceutical-grade biopolymers, by inaugurating a new production unit dedicated to sterile hyaluronic acid at its Javené (Ille-et-Vilaine) site, a true flagship of French biomanufacturing. With over 30 years of expertise in biopolymers, HTL Biotechnology is reaffirming its commitment through this new production unit to the development of innovative therapeutic solutions for the medicine of today and tomorrow. The manufacture of sterile hyaluronic acid opens the way to new therapeutic opportunites . This cutting-edge process now makes it possible to combine hyaluronic acid with heat-sensitive active molecules, previously incompatible with traditional heat sterilization methods. Simultaneously, mastery of aseptic processes eliminates any risk of microbial contamination and ensures optimum pharmaceutical quality. This innovation marks a decisive step in the development of new combined formulations, bringing improved clinical benefits for patients in many fields, such as ophthalmology and drug delivery. This €12 million investment, part of HTL Biotechnology's €100 million 2022-2026 strategic plan, pursues two main goals: to explore new opportunities in bioproduction, and to strengthen the company's position as a key player in future applications of hyaluronic acid in healthcare. Production is scheduled to start in 2026, following qualification and validation of the industrial equipment. To guarantee the quality and efficiency of this new production unit, HTL Biotechnology has set up specific in-house training courses to instruct its staff in aseptic procedures and the handling of this new product. Because of the highly technical nature of this product, a team of ten specialists has been trained in the specific skills required for its production ensuring the highest quality standards. François Fournier, CEO of HTL Biotechnology, states: " I'm delighted with the prospects this investment gives us for further innovation in pharmaceutical-grade biopolymers. The breadth and complementarity of our portfolio is unique, and we are proud to be able to serve our customers even better. Thanks to this new unit, promising future applications can be explored, offering innovative solutions for the benefit of patients. I am delighted to be able to count on this new facility, which makes our historic Javené site a true flagship for French bioproduction." As an active member of France Biolead, HTL Biotechnology is proud to take part in the second National Biomanufacturing and Biomedicines Day, which this year enjoys the patronage of French President Emmanuel Macron. The company welcomes this recognition, which underscores the strategic importance of the French biomanufacturing and biomedical industry, at the heart of the challenges facing public health, and France. About HTL HTL Biotechnology is a French biotech company and world leader in the development and responsible biomanufacturing of pharmaceutical-grade biopolymers (Hyaluronic Acid, Polynucleotides and soon recombinant human collagen). These biopolymers are used by healthcare companies to develop treatments in a variety of leading therapeutic areas such as ophthalmology, dermatology, medical aesthetics and rheumatology. HTL Biotechnology recently strengthened its position as world leader in the development of pharmaceutical-grade biopolymers by acquiring, through its subsidiary HTL Biotechnology Innovation Inc. (HTL BII - New Jersey), a recombinant protein platform whose most advanced product is recombinant human collagen type III (rhCOL3) at a world-class scientific research center. To meet the world's growing need for biopolymers, the company also has subsidiaries in Asia and is building a neuromodulator production unit in the United States (HTL BMI - Massachusetts). Historically based in Javené (Brittany - France), the company brings together production, innovation, R&D , as well as quality activities on its site. HTL Biotechnology employs nearly 300 people worldwide. Press contact
Korea Herald
a day ago
- Korea Herald
Biotropics Malaysia Berhad Signs Strategic MOU with ASK Intercity Co., Ltd. to Bring Physta® Tongkat Ali to the Japanese Market
KUALA LUMPUR, June 6, 2025 /PRNewswire/ -- In a significant move to advance natural, evidence-based health solutions in Japan, Biotropics Malaysia Berhad has signed a Memorandum of Understanding (MOU) with ASK Intercity Co., Ltd. for the sales and distribution of Physta ® Tongkat Ali, Biotropics' proprietary standardized extract, in the Japanese market. The MOU signing took place at the Malaysian Pavillion of the World Expo Osaka 2025, during the opening of 'Sustainable Agriculture Week' witnessed by The Honorable Datuk Seri Haji Mohamad bin Sabu, Minister of Agriculture and Food Security. This partnership unites two companies with a shared commitment to the development and marketing of high-quality, clinically supported herbal ingredients. With decades of industry experience, both companies are dedicated to raising the standards of natural product innovation through scientific rigor, transparency and product integrity. Physta ® Tongkat Ali, developed through a landmark collaboration between the Malaysian Government and the Massachusetts Institute of Technology (MIT), stands as one of the world's most clinically studied Tongkat Ali (Eurycoma longifolia) extracts. It is backed by over 20 clinical studies and has been shown to support energy, vitality, libido, immunity, stress management and hormonal health. Recently, new research from Biotropics has uncovered Physta ® 's efficacy in supporting hormonal balance and reducing stress in pre- and postmenopausal women—a breakthrough expansion from its earlier positioning as a male-centric supplement. This positions Physta ® as a versatile ingredient for a broader demographic, supporting both men and women in managing age-related health challenges naturally. "In light of Japan's rapidly ageing population and growing demand for preventive, plant-based health solutions, we believe Physta ® brings timely and relevant benefits," said Haliza Ramli, CEO of Biotropics Malaysia. "There is a surge of interest for Tongkat Ali globally and this collaboration reflects a mutual vision: to deliver clinically supported, high-quality herbal ingredients that meet the needs of discerning, health-conscious consumers." Koichi Hosaka, CEO and Managing Director of ASK Intercity, added, "We are excited to work with Biotropics, a globally respected leader in herbal research. Tongkat Ali is already recognized internationally, and we believe Physta ® will be very appealing to Japanese consumers seeking natural vitality, stress support, hormonal balance and even looking for Power of Malaysian original forest". The partnership arrives at a pivotal time: Japan has the world's oldest population, with over 29% aged 65 and above. As healthy ageing becomes a national priority, ingredients like Physta ® —with proven benefits and gender-inclusive applications—offer real value to brand owners formulating for this dynamic segment. The MOU aims to redefine natural wellness in one of Asia's most mature and discerning health markets and sets foundation for future cooperation between Malaysia and Japan in the field of herbal science, innovation and market development. Biotropics' portfolio—including BioKesum ®, SLP+ ®, Nu-Femme ®, and Eurecta ® —continues to expand, driven by strong IP, clinical validation and Malaysia's rich botanical heritage.
Korea Herald
2 days ago
- Korea Herald
FutureCeuticals, Inc. Announces Peer-Reviewed Publication Highlighting Cellular Health and Immune Support Benefits of vitAlign®
MOMENCE, Ill., June 5, 2025 /PRNewswire/ -- New research published in the International Journal of Molecular Sciences shows that vitAlign®, a proprietary and comprehensive healthy aging innovation from FutureCeuticals, delivers significant benefits for restoring cellular health and supporting a healthy immune response. The study highlights vitAlign's effectiveness in regulating cellular function and metabolic imbalances associated with immune stressors—from the seasonal cold and flu to more complex environmental and immune-related challenges. Researchers evaluated the impact of a low, 50 mg dose of vitAlign in medically stable adults aged 40–55 recovering from a moderate course of COVID-19, as defined by CDC guidelines. The study compared vitAlign to a 1000 mg dose of Vitamin C, focusing on key markers and processes that directly impact immune and cellular health. Results showed that vitAlign significantly reduced excessive reactive oxygen species (ROS) production in mitochondria and through the NOX2 and iNOS pathways—key mechanisms that influence immune and cellular function. Additionally, researchers observed increased levels of circulating, bioavailable nitric oxide, suggesting support for endothelial function and cardiovascular health. The authors noted that the increase in nitric oxide is likely attributable to vitAlign's ability to regulate multiple pathways of ROS production. Notably, vitAlign delivered measurable effects within 30 minutes, lasting up to three hours. In contrast, Vitamin C, which was used as a positive control, was administered at twenty times the dose and did not demonstrate comparable broad-spectrum activity. "These findings build on over a decade of published clinical research establishing vitAlign as a significant cellular health innovation, now extended directly to immune function," said J. Randal Wexler, FutureCeuticals' General Counsel and Vice President of R&D. "Previously, we've shown that vitAlign improves cellular energy efficiency and helps restore metabolic balance, both acutely and over time." Wexler added, "These new results, which compare favorably to a well-known antioxidant like Vitamin C, reinforce vitAlign's potential as a multi-faceted phytonutrient formula, providing broad support for healthy aging, cardiovascular health, and immune function. Our partners are excited about what this means for product innovation and their customers looking for daily cellular health support." About FutureCeuticals: FutureCeuticals, Inc. is the developer of vitAlign and a leader in the research, development, and manufacture of plant-based powders and extracts for the functional food, beverage, and dietary supplement markets.
